Previous issue | Volume 95 | ESPE2022 | Next issue

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

Card image cap
The 60th ESPE Annual Meeting will now be taking place in Rome, Italy.

Poster Category 2

GH and IGFs

hrp0095p2-144 | GH and IGFs | ESPE2022

Growpati Study: Clinical and genetic characterization of a cohort of patients with short stature due to severe primary IGF1 deficiency

Stoupa Athanasia , Flechtner Isabelle , Viaud Magali , Pinto Graziella , Samara-Boustani Dinane , Gonzalez-Briceno Laura , Thalassinos Caroline , Amselem Serge , Legendre Marie , Netchine Irene , Brioude Frederic , Polak Michel

Background: Severe primary insulin-growth factor-1 (IGF1) deficiency (SPIGF1D) is a rare cause of short stature. Diagnosis is based on low basal IGF1 concentration, short stature, normal or elevated growth hormone concentrations and absence of any secondary causes of growth failure. Thanks to advances in next-generation sequencing (NGS) technologies, genetic etiology of SPIGF1D is expanding.Objectives: • Identify th...

hrp0095p2-145 | GH and IGFs | ESPE2022

A user-centred approach to improve digital health solutions in patients requiring growth hormone therapy: Results of a participatory workshop

Alherbish Abdullah , Kaplan Walid , Fernandez-Luque Luis , Rivera-Romero Octavio , Tamer Eladly Farag , Martin O. Savage , Koledova Ekaterina

Background: Digital health is becoming increasingly important worldwide. However, there is a lack of research on barriers to the implementation of digital health solutions for growth disorders in the Gulf Region. Participatory research can help to understand barriers faced by different stakeholders, design effective solutions and evaluate their implementation, whilst taking cultural aspects into consideration. Involving clinicians in understanding barriers to ...

hrp0095p2-146 | GH and IGFs | ESPE2022

GH responsiveness and IGF1 P2 promotor methylation

Apel Anja , I. Iliev Daniel , Urban Christina , Weber Karin , Schweizer Roland , Blumenstock Gunnar , Pasche Sarah , Nieratschker Vanessa , Binder Gerhard

Background: The methylation of IGF1 promoter P2 was reported to negatively correlate with serum IGF-1 concentration and rhGH treatment response in children with idiopathic short stature. These findings have not yet been confirmed.Objective: This study aimed to determine IGF1 promoter P2 methylation in short children treated with rhGH and correlate clinical parameters with the methylation status. In addition, long-term st...

hrp0095p2-147 | GH and IGFs | ESPE2022

Perception of long-acting growth hormone- data from two surveys in Austria

Belic Jelena , Riedl Stefan , Windisch Manfred

Background: Due to its short half-life, conventional biosynthetic human growth hormone needs to be given daily which may represent a burden for patients and their families. Novel long-acting growth hormone (GH) formulations are under development and enable reduced injection frequency through once weekly administration. Two surveys were designed to collect first insights and expectations towards new long-acting formulations. Metho...

hrp0095p2-148 | GH and IGFs | ESPE2022

Height Velocity in Indonesian Children Receiving Growth Hormone Therapy

B Pulungan Aman , A Andarie Attika , Lestari Pramesti Dwi

Background: Short stature is one of the most common conditions referred to pediatric endocrinology clinics, and treatment with growth hormone (GH) is useful to improve height velocity and adult height, but response may be variable. Growth hormone therapy is indicated in several conditions in pediatric patients, including growth hormone deficiency (GHD) and children born short for gestational age (SGA). We investigated differences in treatment response in Indon...

hrp0095p2-149 | GH and IGFs | ESPE2022

Advancing personalised medicine for growth hormone delivery: mixed-methods participatory study of a next generation, smart auto-injector device

I Labarta José , Rivera-Romero Octavio , Fernández-Luque Luis , Keiser Matthew , Koledova Ekaterina

Background: Treatment of growth hormone deficiency (GHD) requires daily injections over multiple years. Novel technologies facilitate this by automating the injection process – thereby adding comfort and reducing anxiety. An always-connected device, enabled by mobile technologies, also facilitates the collection of injection data such that adherence information is available to healthcare professionals (HCPs) in real-time. In developing new solutions, it ...

hrp0095p2-150 | GH and IGFs | ESPE2022

Alterations in stem cell populations during rIgF-1 (Increlex) therapy in patients with SPIGF1D

Bossowski Artur , Grubczak Kamil , Stożek Karolina , Starosz Aleksandra , Bossowski Filip , Moniuszko Marcin

Pathway involving insulin-like growth factor 1 (IGF-1) plays significant role in growth and development. Crucial role of IGF-1 was discovered inter alia through studies involving deficient patients with short stature, including SPIGFD individuals. Noteworthy, despite disturbances in proper growth, elevated values for selected stem cell populations were found in IGF-1 deficient patients. Therefore, here we focused on investigating role of these cells - very small embryonic-like...

hrp0095p2-151 | GH and IGFs | ESPE2022

A novel mutation of LHX3 is associated with combined hypopituitarism and dysmorphic face

Noorian Shahab , Savad Shahram , Saffari Fatemeh , Nikkhah Saeed , Talea Ali , Soltani Hedieh

The pituitary gland is a pea-sized organ located at the base of the brain. It synthesizes, and secretes, many hormones that control growth and development, and the functioning of the other endocrine glands. Panhypopituitarism is a condition of inadequate or absent production of all these hormones. LHX3 (LIM Homeobox 3) is a Protein-Coding gene involved in pituitary development. Mutations in this gene may result in a deficiency of multiple pituitary hormones. Here, we present a...

hrp0095p2-152 | GH and IGFs | ESPE2022

IGF1 as reassessment method of GH deficiency in adulthood

Belen Ariza-Jimenez Ana , Antonio Ariza-Jimenez Jose , Jose Martinez-Aedo Ollero Maria , Pedro Lopez-Siguero Juan

Background: GH deficiency may not persist into adulthood. Thus, it is recommended to reassess it after reaching adult height. However, according to stimulation tests, they have poor specificity, reproducibility, and poor standardization of hormonal measurement, and they are expensive and involve risks.Objective and hypotheses: Establish if IGF1 would be a better reassessing method than stimulation tests in adult GH defic...

hrp0095p2-153 | GH and IGFs | ESPE2022

Avascular necrosis of the hip as a rare complication of growth hormone therapy

van der Linde Annelieke , van Baelen Amber , van Bergen Christiaan

Background: Growth hormone therapy can be indicated for children who are born small for gestation age (SGA) (either birth weight or birth height < -2 SDS) without catch-up growth (height < -2.5 SDS) at age 4 years. Growth hormone therapy is considered a safe treatment.Case presentation: A 12-year-old girl was referred to the pediatric endocrinologist for short stature. She was born small for gestational age (birth ...

hrp0095p2-154 | GH and IGFs | ESPE2022

Predictive Factors of Adult Height After 2 Years of GH Replacement Therapy in Children with Growth Hormone Deficiency (GHD)

Mastromauro Concetta , Polidori Nella , Gentile Cristina , Chiarelli Francesco , Mohn Angelika , Giannini Cosimo

Introduction: Growth Hormone Deficiency (GHD) represents the most common hormone deficiency during childhood accounting for 3% of causes of short stature. Although growth hormone (GH) replacement therapy is available, several studies have shown a different response in terms of height. Therefore, some reports have tried to characterize predictive factors able to define growth gain during treatment.Objective: Therefore, th...

hrp0095p2-155 | GH and IGFs | ESPE2022

Poor efficacy of growth hormone treatment in a patient with fetal alcohol syndrome

Koga Nobuhiko , Sasaoka Daiki , Tanaka Yukari , Sasaki Fusako , Yatsuga Shuichi , Nagamitsu Shinichiro Nagamitsu Shinichiro

Fetal alcohol syndrome (FAS) is established based on the presence or absence of characteristic facial features, prenatal/postnatal growth deficiency (height and/or weight < 10th percentile), deficient brain growth, neurobehavioral impairment, and maternal alcohol consumption during pregnancy. There have been no reports of growth hormone (GH) treatment in FAS; therefore, we report a case of GH treatment on FAS for small for gestational (SGA) short stature. The patient was a ...

hrp0095p2-156 | GH and IGFs | ESPE2022

Short Term Effects of Growth Hormone in Children and Adolescents with Growth Hormone Deficiency

Tawfik Sameh , Hassan Mona , Attia Mona , Atef Abeer , Mira Marwa , Dowidar Wafaa , Elkhashab Khaled , Diab Wala

Introduction: Children with Growth Hormone deficiency(GHD) should be treated with r-hGH as early as possible after the diagnosis is made. The primary objectives of therapy is to normalize growth during childhood and to achieve final height within their genetic potential.Objectives: To determine impact of GH treatment on short term linear growth in the 1st year of therapy in children with isolated growth hormone deficienc...

hrp0095p2-157 | GH and IGFs | ESPE2022

Prevalence of Childhood Short Stature and weight variations Among Primary School Children

Berrabeh Soumiya , Bouali Houda , Boujtat Khadija , Assarrar Imane , Rouf Siham , Latrech Hanane

Keywords: short stature, underweight, overweight, obesityIntroduction: Natural growth is an important indicator of health in childhood. Growth retardation can result from systemic and endocrine diseases or poor diet. Being overweight or obese in childhood increases the risk of morbidity and mortality in adulthood. This study, the first of its kind in Morocco, was conducted to compare the prevalence of growth disorders am...